Patents Assigned to ID Biomedical
  • Patent number: 7524509
    Abstract: An adjuvant complex composed of bacterial outer membrane protein proteosomes complexed to bacterial liposaccharide is prepared to contain the component parts under a variety of conditions. The complex can be formulated with antigenic material to form immunogenic compositions, vaccines and immunotherapeutics. An induced immune response includes protective antibodies and/or type 1 cytokines is shown for a variety of protocols.
    Type: Grant
    Filed: March 11, 2002
    Date of Patent: April 28, 2009
    Assignee: ID Biomedical Corporation of Quebec
    Inventors: David S. Burt, George H. Lowell, Gregory L. White, David Jones, Clement Rioux
  • Patent number: 7482012
    Abstract: The present invention relates to antigens, more particularly antigens of Streptococcus pyogenes (also called group A Streptococcus (GAS)) bacterial pathogen which are useful as vaccine component for prophylaxis, therapy and/or diagnostic.
    Type: Grant
    Filed: February 21, 2002
    Date of Patent: January 27, 2009
    Assignee: ID Biomedical Corporation
    Inventors: Denis Martin, Stephane Rioux, Bernard R. Brodeur, Josee Hamel, Patrick Rheault
  • Patent number: 7459165
    Abstract: The present invention relates to polypeptides of Pseudomonas aeruginosa which may be used to prevent, diagnose and/or treat Pseudomonas aeruginosa infection.
    Type: Grant
    Filed: November 13, 2002
    Date of Patent: December 2, 2008
    Assignee: ID Biomedical Corporation
    Inventors: Nathalie Charland, Josee Hamel, Bernard Brodeur, Denis Martin, Isabelle Charlebois, Diane Bussiere
  • Patent number: 7410648
    Abstract: The present invention relates to polypeptides, more particularly polypeptides of Moraxella (Branhamella) catarrhalis which may be used to prevent, diagnose and/or treat Moraxella (Branhamella) catarrhalis infection.
    Type: Grant
    Filed: November 15, 2002
    Date of Patent: August 12, 2008
    Assignee: ID Biomedical Corporation
    Inventors: Denis Martin, Josée Hamel, Bernard R. Brodeur, Stéphane Rioux, Julie Couture
  • Patent number: 7410645
    Abstract: The present invention relates to polypeptides of Moraxella(Branhamella) catarrhalis which may be useful for prophylaxis, diagnosis and/or therapy purposes.
    Type: Grant
    Filed: May 15, 2002
    Date of Patent: August 12, 2008
    Assignee: ID Biomedical Corporation
    Inventors: Denis Martin, Josée Hamel, Bernard R. Brodeur, Stéphane Rioux, Julie Couture
  • Publication number: 20080175868
    Abstract: Effective stimulation of immune responses is achieved through the use of a group A streptococcal antigen combined with proteosome adjuvant. The compositions are provided in particular for intranasal administration. The vaccine compositions are provided for use in inducing an immune response in an individual for the treatment or prophylaxis of group A streptococcal infection in an individual, preferably via prevention or reduction of colonisation of the throat following intranasal administration.
    Type: Application
    Filed: July 24, 2007
    Publication date: July 24, 2008
    Applicants: ID Biomedical Corporation of Quebec, The Council of the Queensland Institute of Medical Research
    Inventors: George H. Lowell, George L. White, Michael Raymond Batzloff, David S. Burt, Tomas B. Leanderson, Michael F. Good
  • Patent number: 7399840
    Abstract: Improved forms of vaccines which comprise proteosomes and protein antigens are described. Vaccines which contain influenza HA as the antigen are used for illustration as to demonstrate efficacy. Improvements in the preparation of the vaccines themselves and the proteosome component are also included.
    Type: Grant
    Filed: February 3, 2004
    Date of Patent: July 15, 2008
    Assignee: ID Biomedical Corporation of Quebec
    Inventors: David S. Burt, David H. Jones, George H. Lowell, Gregory L. White, Kirkor Torossian, Louis F. Fries, III, Martin Plante
  • Patent number: 7393536
    Abstract: The present invention relates to antigens, more particularly antigens of Group B Streptococcus (GBS) (S. agalactiae) which may be useful to prevent, diagnose and/or treat streptococcal infections.
    Type: Grant
    Filed: July 5, 2002
    Date of Patent: July 1, 2008
    Assignee: ID Biomedical Corporation
    Inventors: Denis Martin, Stéphane Rioux, Bernard R. Brodeur, Josée Hamel, Martine Boyer
  • Patent number: 7368537
    Abstract: The present invention relates generally to methods of treating or preventing RSV infections, and more specifically, to compositions, and the use thereof, comprising one or more RSV G protein immunogen or fragment thereof capable of eliciting protective immunity without eliciting an immunopathological response or eliciting a reduced immunopathological response.
    Type: Grant
    Filed: July 9, 2004
    Date of Patent: May 6, 2008
    Assignee: ID Biomedical Corporation of Quebec
    Inventors: Robert Anderson, Yan Huang, David S. Burt
  • Patent number: 7335368
    Abstract: Group B streptococcus polypeptides and polynucleotides encoding them are disclosed. Said polypeptides may be useful for the prophylaxis, diagnostic and/or therapy of streptococcal infection in mammals. Also disclosed are recombinant methods of producing the polypeptide antigens as well as diagnostic assays for detecting streptococcal infections, particularly GBS.
    Type: Grant
    Filed: October 15, 2001
    Date of Patent: February 26, 2008
    Assignee: ID Biomedical Corporation
    Inventors: Denis Martin, Stephane Rioux, Martine Boyer, Josée Hamel, Bernard R Brodeur
  • Publication number: 20080038268
    Abstract: The present invention relates to antigens, more particularly an antigen of Streptococcus pyogenes (also called group A Streptococcus (GAS)) bacterial pathogen which is useful as vaccine component for therapy and/or prophylaxis.
    Type: Application
    Filed: July 9, 2007
    Publication date: February 14, 2008
    Applicant: ID Biomedical Corporation
    Inventors: Denis Martin, Josee Hamel, Bernard Brodeur, Stephane Rioux, Martine Boyer
  • Patent number: 7329500
    Abstract: The present invention relates to polypeptides of Moraxella (Branhamela) catarrhalis which may be used for prophy-laxis, diagnostic and/or therapy purposes.
    Type: Grant
    Filed: August 27, 2002
    Date of Patent: February 12, 2008
    Assignee: ID Biomedical Corporation
    Inventors: Denis Martin, Josée Hamel, Bernard R. Brodeur, Stéphane Rioux, Julie Couture
  • Patent number: 7273611
    Abstract: The identification of a highly conserved, immunologically accessible antigen on the surface of Neisseria facilitates treatment, prophylaxis, and diagnosis of Neisseria diseases. This antigen is highly resistant to proteinase K and has an apparent molecular weight of 22 kDa on SDS-PAGE. Specific polynucleotides encoding proteins of this class have been isolated from three Neisseria meningitidis strains and from one Neisseria gonorrhoaea strain. These polynucleotides have been sequenced, and the corresponding full-length amino acid sequences of the encoded polypeptides have been deduced. Recombinant DNA methods for the production of the Neisseria surface protein, and antibodies that bind to this protein are also disclosed.
    Type: Grant
    Filed: October 6, 2000
    Date of Patent: September 25, 2007
    Assignee: ID Biomedical Corporation
    Inventors: Bernard R. Brodeur, Denis Martin, Josee Hamel, Clement Rioux
  • Patent number: 7270827
    Abstract: Compositions and methods for making and using therapeutic formulations of multivalent hybrid polypeptides comprising immunogenic peptides of M proteins from various different serotypes of group A streptococci and antibodies thereto are provided. Also provided are nucleic acids encoding such hybrid polypeptides. The hybrid polypeptide formulations may be used, for example, in methods for treating or preventing a microbial infection and eliciting a protective immune response having broadly protective opsonic antibodies in the absence of tissue cross-reactive antibodies.
    Type: Grant
    Filed: October 28, 2002
    Date of Patent: September 18, 2007
    Assignees: University of Tennessee Research Foundation, ID Biomedical Corporation of Washington
    Inventors: Mark A. Reddish, Mary ChaoHong Hu, Michael A. Walls, James B. Dale
  • Patent number: 7262024
    Abstract: The present invention relates to polypeptides of Streptococcus pneumoniae which may be used for prophylaxis, diagnostic and/or therapy purposes.
    Type: Grant
    Filed: December 20, 2002
    Date of Patent: August 28, 2007
    Assignee: ID Biomedical Corporation
    Inventors: Josée Hamel, Nathalie Charland, Bernard R. Brodeur, Denis Martin, Normand Blais, Catherine Ouellet, Steve Labbe
  • Patent number: 7255867
    Abstract: Effective stimulation of immune responses is achieved through the use of a group A streptococcal antigen combined with proteosome adjuvant. The compositions are provided in particular for intranasal administration. The vaccine compositions are provided for use in inducing an immune response in an individual for the treatment or prophylaxis of group A streptococcal infection in an individual, preferably via prevention or reduction of colonisation of the throat following intranasal administration.
    Type: Grant
    Filed: November 13, 2003
    Date of Patent: August 14, 2007
    Assignees: ID Biomedical Corporation of Quebec, The Council of the Queensland Institute of Medical Research
    Inventors: George H Lowell, George L White, Michael R Batzloff, David S Burt, Tomas B Leanderson, Michael F Good
  • Patent number: 7247308
    Abstract: The present invention relates to antigens, more particularly an antigen of Streptococcus pygenes (also called group A Streptococcus (GAS)) bacterial pathogen which is useful as vaccine component for therapy and/or prophylaxis.
    Type: Grant
    Filed: July 6, 2001
    Date of Patent: July 24, 2007
    Assignee: ID Biomedical Corporation
    Inventors: Denis Martin, Josee Hamel, Bernard Brodeur, Stephane Rioux, Martine Boyer
  • Publication number: 20070116712
    Abstract: Streptococcus proteins and polynucleotides encoding them are disclosed. Said proteins are antigenic and therefore useful vaccine components for the prophylaxis or therapy of streptococcus infection in animals. Also disclosed are recombinant methods of producing the protein antigens as well as diagnostic assays for detecting streptococcus bacterial infection.
    Type: Application
    Filed: August 29, 2006
    Publication date: May 24, 2007
    Applicant: ID Biomedical Corporation
    Inventors: Josee Hamel, Bernard Brodeur, Isabelle Pineau, Denis Martin, Clement Rioux, Nathalie Charland
  • Publication number: 20070110766
    Abstract: The identification of a highly conserved, immunologically accessible antigen at the surface of Neisseria facilitates treatment, prophylaxis, and diagnosis of Neisseria diseases. This antigen is highly resistant to Proteinase K and has an apparent molecular weight of 22 kDa on SDS-PAGE. Specific polynucleotides encoding proteins of this class have been isolated from three Neisseria meningitidis strains and from one Neisseria gonorrhoeae strain. These polynucleotides have been sequenced, and the corresponding full-length amino acid sequences of the encoded polypeptides have been deduced. Recombinant DNA methods for the production of the Neisseria surface protein, and antibodies that bind to this protein are also disclosed.
    Type: Application
    Filed: October 16, 2006
    Publication date: May 17, 2007
    Applicant: ID Biomedical Corporation
    Inventors: Bernard Brodeur, Denis Martin, Josee Hamel, Clement Rioux
  • Publication number: 20060286124
    Abstract: The present disclosure relates to compositions and methods for treating or preventing coronavirus infections. For example, compositions are provided that comprise a coronavirus S protein or N protein, fragment, or variant thereof, capable of eliciting a protective humoral and/or cell-mediated immune response, which compositions are useful for treating or preventing infection by coronavirus, such as the causative agent of SARS. Also, coronavirus S protein and N protein immunogen compositions are provided that include an adjuvant, such as Proteosome or Protollin, which may be used for treating or preventing infection caused by a coronavirus, such as a SARS coronavirus.
    Type: Application
    Filed: June 30, 2005
    Publication date: December 21, 2006
    Applicant: ID Biomedical Corporation of Quebec
    Inventors: David Burt, Mark Reddish, Mary Hu, George Lowell, David Jones